Hexagon Capital Partners LLC Buys 51 Shares of Eli Lilly and Company (NYSE:LLY)

Hexagon Capital Partners LLC increased its stake in Eli Lilly and Company (NYSE:LLY) by 8.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 639 shares of the company’s stock after purchasing an additional 51 shares during the quarter. Hexagon Capital Partners LLC’s holdings in Eli Lilly and Company were worth $372,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. International Assets Investment Management LLC raised its holdings in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after acquiring an additional 7,330,815 shares during the period. Sapient Capital LLC bought a new stake in Eli Lilly and Company during the fourth quarter valued at about $617,312,000. J.P. Morgan Private Wealth Advisors LLC bought a new stake in Eli Lilly and Company during the third quarter valued at about $435,736,000. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after acquiring an additional 659,838 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its holdings in Eli Lilly and Company by 24.2% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,310,859 shares of the company’s stock valued at $1,778,362,000 after acquiring an additional 645,473 shares during the period. 82.53% of the stock is owned by institutional investors.

Analysts Set New Price Targets

LLY has been the topic of a number of recent analyst reports. BMO Capital Markets raised their price target on Eli Lilly and Company from $710.00 to $865.00 and gave the company an “outperform” rating in a report on Wednesday, February 7th. Cantor Fitzgerald reissued an “overweight” rating and set a $885.00 price target (up from $815.00) on shares of Eli Lilly and Company in a report on Tuesday. Barclays raised their price target on Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. TheStreet raised Eli Lilly and Company from a “c+” rating to a “b” rating in a report on Friday, March 8th. Finally, The Goldman Sachs Group lifted their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a report on Thursday, April 11th. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $733.65.

Eli Lilly and Company Trading Down 0.7 %

Shares of Eli Lilly and Company stock traded down $5.26 on Wednesday, hitting $775.84. 689,474 shares of the company traded hands, compared to its average volume of 3,041,018. The stock’s 50 day moving average price is $761.41 and its 200-day moving average price is $669.21. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 52 week low of $399.26 and a 52 week high of $800.78. The company has a market cap of $737.17 billion, a PE ratio of 133.85, a PEG ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to the consensus estimate of $8.94 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s revenue was up 26.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.62 earnings per share. Equities research analysts predict that Eli Lilly and Company will post 12.51 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.